{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.7241","value":"1.198"},{"groupId":"OG001","spread":"0.7381","value":"1.653"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"description":"Cycle nadir was the lowest value for ANC that occurred between start of cycle and end of cycle and was less than the cycle baseline.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received trilaciclib 200 mg/m\\^2 administered intravenously (IV) once daily on Days 1 to 3 of each 21-day E/P chemotherapy cycle.","id":"OG000","title":"Part 1: Cohort 1 Trilaciclib 200 mg/m^2"},{"description":"Participants received trilaciclib 240 mg/m\\^2 administered IV once daily on Days 1 to 3 of each 21-day E/P chemotherapy cycle.","id":"OG001","title":"Part 1: Cohort 2 Trilaciclib 240mg/m^2"}],"paramType":"MEAN","populationDescription":"The FAS included all randomized patients who received at least 1 dose of study drug (etoposide, carboplatin, or trilaciclib). Analyses using the FAS were conducted on the basis of the assigned treatment.","reportingStatus":"POSTED","timeFrame":"From baseline to the end of Cycle 1","title":"Nadir of Absolute Neutrophil Count in Cycle 1, Part 1","type":"SECONDARY","unitOfMeasure":"x 10^9 cells/L"}